Breakdown | ||||
Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|
Income Statement | Total Revenue | |||
174.43M | 106.34M | 97.95M | 130.58M | 138.14M | Gross Profit |
84.26M | 50.45M | 37.05M | 69.37M | 83.33M | EBIT |
-175.24M | -76.60M | -116.20M | -67.46M | -51.04M | EBITDA |
-118.14M | -54.46M | -173.57M | -43.77M | -34.60M | Net Income Common Stockholders |
-138.88M | -74.66M | -190.10M | -59.24M | -53.02M |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
292.87M | 114.89M | 165.78M | 28.45M | 68.52M | Total Assets |
612.34M | 323.07M | 390.31M | 275.21M | 324.76M | Total Debt |
33.00M | 98.21M | 102.66M | 111.65M | 95.38M | Net Debt |
-133.73M | 46.51M | 21.35M | 83.20M | 26.86M | Total Liabilities |
140.62M | 159.87M | 471.78M | 180.62M | 185.71M | Stockholders Equity |
471.72M | 163.20M | -81.47M | 94.60M | 139.05M |
Cash Flow | Free Cash Flow | |||
-151.81M | -46.12M | -93.19M | -57.33M | -28.13M | Operating Cash Flow |
-143.45M | -43.29M | -89.37M | -44.06M | -15.42M | Investing Cash Flow |
363.17M | 20.24M | -88.13M | -11.95M | 39.98M | Financing Cash Flow |
-102.62M | -6.81M | 230.76M | 15.96M | 20.86M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
65 Neutral | $491.41M | 30.59 | -1.20% | ― | 38.43% | 86.19% | |
59 Neutral | $648.14M | ― | -3.61% | ― | 1.71% | 76.00% | |
57 Neutral | $454.87M | ― | -51.25% | ― | 15.57% | 31.82% | |
54 Neutral | $5.28B | 3.29 | -45.38% | 2.80% | 16.77% | -0.08% | |
52 Neutral | $1.09B | ― | -3.04% | ― | -13.79% | 82.82% | |
51 Neutral | $487.62M | ― | -13.84% | ― | 12.15% | 61.33% | |
49 Neutral | $410.21M | ― | -25.73% | ― | 33.86% | 64.34% |
Standard BioTools reported its financial results for the first quarter of 2025, showing a revenue of $40.8 million, a 10% decrease from the previous year. Despite the revenue decline, the company achieved a 45% reduction in operating loss and a 29% improvement in adjusted EBITDA, attributed to cost reductions and productivity gains. The company maintains a strong balance sheet with $261 million in cash and no material debt. The strategic focus on proteomics and the upcoming launch of a new NGS-based product are expected to drive future growth.